5-fluoro-4-methylpyridin-3-amine | 1402672-74-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-fluoro-4-methylpyridin-3-amine
• CAS: 1402672-74-5
• 化学式: C₆H₇FN₂
• 分子量: 126.133
• InChiKey: QAAPAUBJMRMMGS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-fluoro-4-methylpyridin-3-amine 、 ethyl (7S)-5-[3-chloro-4-(trifluoromethyl)phenyl]-7-methyl-4-oxo-6,7-dihydropyrazolo[1,5-a]pyrazine-3-carboxylate 在 乙基溴化镁 作用下， 以 四氢呋喃 为溶剂， 反应 19.0h， 以36%的产率得到(7S)-5-[3-chloro-4-(trifluoromethyl)phenyl]-N-(5-fluoro-4-methyl-3-pyridyl)-7-methyl-4-oxo-6,7-dihydropyrazolo[1,5-a]pyrazine-3-carboxamide
  参考文献：
  名称：

  [EN] 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
  [FR] COMPOSÉS DE 6,7-DIHYDROPYRAZOLO [1,5-Α]PYRAZIN -4 (5H)-ONE ET LEUR UTILISATION EN TANT QUE MODULATEURS NÉGATIFS ALLOSTÉRIQUES DES RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE

  摘要：

  公开号：

  WO2016016380A8
• 作为产物：
  描述：

  tert-butyl (5-fluoropyridin-3-yl)carbamate 在 正丁基锂 、 三氟乙酸 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 为溶剂， 反应 4.5h， 生成 5-fluoro-4-methylpyridin-3-amine
  参考文献：
  名称：

  [EN] 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
  [FR] COMPOSÉS DE 6,7-DIHYDROPYRAZOLO [1,5-Α]PYRAZIN -4 (5H)-ONE ET LEUR UTILISATION EN TANT QUE MODULATEURS NÉGATIFS ALLOSTÉRIQUES DES RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE

  摘要：

  公开号：

  WO2016016380A8

文献信息

• Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of MGLUR2 receptors
  申请人：Janssen Pharmaceutica NV

  公开号：US10005786B2

  公开（公告）日：2018-06-26

  The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives of Formula (I) as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.

  本发明涉及式 (I) 的新型 6,7-二氢吡唑并[1,5-a]吡嗪-4(5H)-酮衍生物 作为代谢型谷氨酸受体亚型 2（"mGluR2"）的负异位调节剂（NAMs）。本发明还涉及包含此类化合物的药物组合物、制备此类化合物和组合物的工艺，以及使用此类化合物和组合物预防或治疗涉及代谢型受体 mGluR2 亚型的疾病。
• Discovery of Orally Efficacious Phosphoinositide 3-Kinase δ Inhibitors with Improved Metabolic Stability
  作者：Leena Patel、Jayaraman Chandrasekhar、Jerry Evarts、Kristen Forseth、Aaron C. Haran、Carmen Ip、Adam Kashishian、Musong Kim、David Koditek、Sandy Koppenol、Latesh Lad、Eve-Irene Lepist、Mary E. McGrath、Stephane Perreault、Kamal D. Puri、Armando G. Villaseñor、John R. Somoza、Bart H. Steiner、Joseph Therrien、Jennifer Treiberg、Gary Phillips

  DOI：10.1021/acs.jmedchem.6b01169

  日期：2016.10.13

  Aberrant signaling of phosphoinositide 3-kinase delta (PI3K delta) has been implicated in numerous pathologies including hematological malignancies and rheumatoid arthritis. Described in this manuscript are the discovery, optimization, and in vivo evaluation of a novel series of pyridine-containing PI3K delta inhibitors. This work led to the discovery of 35, a highly selective inhibitor of PI3K delta which displays an excellent pharmacokinetic profile and is efficacious in a rodent model of rheumatoid arthritis.
• 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
  申请人：Janssen Pharmaceutica NV

  公开号：US20170217972A1

  公开（公告）日：2017-08-03

  The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.
• SUBSTITUTED 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
  申请人：Janssen Pharmaceutica NV

  公开号：US20200121677A1

  公开（公告）日：2020-04-23

  The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.
• [EN] 6,7-DIHYDROPYRAZOLO[1,5-α]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS<br/>[FR] COMPOSÉS DE 6,7-DIHYDROPYRAZOLO [1,5-Α]PYRAZIN -4 (5H)-ONE ET LEUR UTILISATION EN TANT QUE MODULATEURS NÉGATIFS ALLOSTÉRIQUES DES RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2016016380A1

  公开（公告）日：2016-02-04

  The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.